MedChemExpress

Master of Bioactive Molecules

Inhibitors • Screening Libraries • Proteins

— www.MedChemExpress.com

MedChemExpress USA

Tel:609-228-6898E-mail:sales@MedChemExpress.comFax:609-228-5909Tech Support:tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

MedChemExpress Europe

Tel: + 46 86500910 E-mail: eu.sales@MedChemExpress.com

Address: Bergkällavägen 37C, 192 79 Sollentuna, SWEDEN

For research use only.
We do not sell to patients

Master of **Bioactive Molecules**


www MedChemExpress com



ONE-STOP COMPOUND SCREENING PLATFORM

MedChemExpress one-stop compound screening platform supplies more than 200 screening libraries and a variety of compounds and phenotypic screening services. These services include DNA-encoded compound library screening, virtual screening, high-throughput screening (HTS), ion channel detection, kinase screening & profiling, phenotypic screening, affinity mass spectrometry screening, customized compound synthesis, structural optimization and analysis services, etc.

We are committed to continuously developing and improving our platform capabilities. Our goal is to creat a one-stop drug discovery service platform suitable for scientific research, and fostering infinite possibilities for innovation.



TOP PUBLICATIONS CITING USE OF MEDCHEMEXPRESS PRODUCTS

Nature. 2023 Apr;616(7957):563-573.

Nature. 2023 Apr;616(7956):348-356.

Nature. 2023 Apr;616(7956):357-364.

Nature. 2023 Apr;616(7958):806-813.

Nature. 2023 Mar:615(7952):490-498.

Nature. 2023 Mar;615(7952):526-534.

Nature. 2023 Mar;615(7951):349-357.

Nature. 2023 Mar:615(7950):127-133.

Nature. 2023 Mar;615(7950):158-167.

Nature. 2023 Feb;614(7947):326-333.

Nature. 2023 Jan;613(7942):187-194.

Nature. 2023 Jan;613(7942):120-129.

Nature. 2022 Dec;612(7941):725-731.

Science. 2022 Dec 2;378(6623):eabo5503.

Science. 2022 Nov 18;378(6621):eabq7361.

Science. 2022 Oct 14;378(6616):eabg0132.

Science. 2022 Jul 8;377(6602):eabg9302.

Science. 2022 Mar 18;375(6586):1254-1261.

Cell. 2023 Apr 27;186(9):1895-1911.e21.

Cell. 2023 Mar 30;186(7):1352-1368.e18.

Cell. 2023 Mar 2;186(5):1026-1038.e20.

Cell. 2023 Feb 16;186(4):850-863.e16.


Cell. 2023 Feb 16;186(4):803-820.e25.

Cell. 2023 Feb 2;186(3):591-606.e23.

Cell. 2023 Jan 19;186(2):346-362.e17.

Cell. 2023 Jan 19;186(2):413-427.e17.

Cell. 2022 Nov 10;185(23):4347-4360.e17.



CONTENTS

↓ Compound Screening Libraries

•	Bioactive Compound Libraries · · · · · · · · · · · · · · · · · · ·	04
•	Drug Repurposing Research · · · · · · · · · · · · · · · · · · ·	05
•	Drug Discovery Based on Natural Products · · · · · · · · · · · · · · · · · · ·	06
•	Drug Discovery Based on Structures · · · · · · · · · · · · · · · · · · ·	07
•	Screening Based on Targets and Signaling Pathways · · · · · · · · · · · · · · · · · · ·	80
•	Drug Discovery Based on Diseases · · · · · · · · · · · · · · · · · ·	10
•	Drug Screening Based on Product Features · · · · · · · · · · · · · · · · · · ·	12
•	Diversity Compound Libraries · · · · · · · · · · · · · · · · · · ·	13
•	DNA-Encoded Compound Libraries · · · · · · · · · · · · · · · · · · ·	14
•	Customize Your Libraries · · · · · · · · · · · · · · · · · · ·	15
•	Case Studies · · · · · · · · · · · · · · · · · · ·	16
•	Parameters of MedChemExpress Compound Libraries	18

•	Virtual Screening · · · · · · · · · · · · · · · · · · ·	19
+	Drug Screening Services	
•	AS-MS Screening · · · · · · · · · · · · · · · · · · ·	20
•	Target Based Screening (GPCR/ Kinase/ Ion Channel) · · · · · · · · · · · · · · · · · · ·	20
•	Anti-Cancer Compounds Screening in Vitro	21
•	Del Screening · · · · · · · · · · · · · · · · · · ·	22
+	Lead Compounds Optimization	
•	Search and Supply of Structure Analogs · · · · · · · · · · · · · · · · · · ·	23
•	Custom Synthesis · · · · · · · · · · · · · · · · · ·	23
•	Analytical Development & Quality Control	23



COMPOUND SCREENING LIBRARIES



- 20,000+ bioactive compounds
- 26 million+ diversity compounds and fragments
- 2 billion DEL molecules



- With more than 10 years of excellent experience in compound synthesis and compound library design
- >8,000 m² R&D center square,
 1.000+ R&D staff
- Serving hundreds of thousands of scientists in more than 50 countries around the world
- Total deliveries exceeded 500,000 tubes of compounds




We provide the full-process drug development services covering compound library supply, screening services, lead compound optimization, and customized synthesis of compounds for preclinical and clinical studies



- Certified by ISO 9001, CNAS quality management system, strict quality control and verification system
- Since 2018, we have successfully cleared over 100 customer audits, with a flawless pass rate of 100%, and 11 third-party audits, including a GMP audit of EU QP
- Equipped with hundreds of state-of-the-art quality inspection equipment. Provide various quality inspection reports, including HNMR, LC/MS, HPLC, chiral analysis, elemental analysis, SEC-HPLC, etc



- Have a global network of multiple business and warehouse logistics centers, sufficient spot reserves, stable supply chains
- 1,000 m² warehouse, stores over 100,000 sample tubes
- Fully automatic storage and selection of samples
- Fully airtight dry gas protection environment from room temperature to -80 °C



HIGH-THROUGHPUT SCREENING LIBRARY

- 26 million+ compounds available for screening
- Suitable for Al-based lead discovery, ultra-large virtual screening
- Diverse and lead-like

DNA-ENCODED COMPOUND LIBRARIES

- 68 DEL libraries with billions of DEL molecules
- · Highly diverse structures, wide chemical space coverage, high target-binding capacities
- Powerful compound synthesis capability
- Customized services

BIOACTIVE COMPOUND LIBRARY

- 200+ bioactive compound libraries
- 22,000+ bioactive compounds can be supplied
- Covering 1,000+ targets and hot research areas

FRAGMENT LIBRARY

- 20,000+ fragment compounds
- Diverse structures
- A useful tool for fragment-based drug discoveries (FBDD)

DIVERSITY COMPOUND LIBRARY

- 100,000+ compounds with highly diverse chemical structures
- Lead-like compounds with excellent bioactivity and high target-binding capacities
- The reliable and rich source for drug screening



BIOACTIVE COMPOUND I IBRARIFS



Bioactive compounds are a general term for a class of substances that can cause specific biological effects in the body, which are the primary source of small molecule drugs. These compounds act on specific target proteins in cell-regulate intracellular signaling pathways, and cause some changes in cell phenotype.



Library Recommendation

HY-L001P Bioactive Compound Library Plus

This library has a full range of bioactive compounds, including natural products, innovative compounds, approved compounds, and clinical compounds. This library is a valuable tool for signal pathway research, drug discovery, repurposing, etc.

HY-L099 Targeted Diversity Library

This library covers more than 1,000 targets and isoforms. 1-3 compounds with high potency and selectivity were carefully selected for each target and isoform. This library is a concise collection of small molecule compounds with comprehensive target coverage, which can be used for phenotypic screening at a low cost.

HY-L111 Novel Bioactive Compound Library

All compounds in this library have validated bioactivities tested by cell-based or biochemical assays. These compounds are structurally novel and bioactivity diverse, which makes it easier to discover new lead compounds.

Strength

- With a full range of product catalogs, including more than 20,000 bioactive compounds.
- · All compounds with high bioactivity and specificity are collected from literature and patents. The cell activity is general between nM to µM.
- Cover more than 1,000 kinds of targets. All compounds have explicit bioactive annotations.
- Most of the compounds have been tested in vivo and have good pharmacokinetic properties and stable metabolism.
- Specially designed to increase potential high-quality hits.
- With high structure diversities, including 136, 000+ Bemis-Murcko scaffolds. The average dissimilarity is 0.9.
- Re-supply of any hit-compound guaranteed from mg level to kg level.

DRUG REPURPOSING RESEARCH





Library Recommendation

HY-L022P FDA-Approved Drug Library Plus

A unique collection of compounds approved by the FDA, EMA, NMPA, and other countries. All compounds have completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety, and bioavailability properties. It's a preferred library for drug repurposing.

Other Drug Repurposing Series

HY-L022	HY-L066
FDA-Approved Drug Library	FDA Approved & Pharmacopeial Drug Library
HY-L026	HY-L026P
Clinical Compound Library	Clinical Compound Library Plus
HY-L035	HY-L035P
Drug Repurposing	Drug Repurposing
Compound Library	Compound Library Plus
HY-L053	HY-l 116
=	20
NMPA-Approved Drug Library	EMA-Approved Drug Library
HY-L112	HY-L104
Chemotherapy Drug Library	Children's Drug Library
HY-L140	HY-L141
Withdrawn Drug Compound Library	Off-Patent Drug Library
Sci Adv. 2022 Oct 7;8(40):eabn9350.	EBioMedicine. 2022 Dec 8:87:10439



Publications Citing Use of MedChemExpress **Compound Libraries**

Nat Microbiol. 2023 Jan;8(1):121-134. Cell Mol Immunol. 2023 Mar 2;1-14.

J Exp Med. 2023 Mar 6;220(3):e20221316. Cell Rep. 2023 Feb 17;42(2):112105. J Cell Biol. 2023 Jan 2;222(1):e202202110. Int J Mol Sci. 2022 Apr 28;23(9):4891. Cell Stem Cell. 2022 Apr 7;29(4):545-558.e13. Nat Cancer. 2022 May;3(5):614-628. JCI Insight. 2022 Aug 8;7(15):e160247. Nat Commun. 2021 Jan 12;12(1):280. Sci Adv. 2021 Dec 24;7(52):eabb3673. Pharmacol Ther. 2021 Dec;228:107930.

Compound Screening Libraries —

DRUG DISCOVERY BASED ON NATURAL PRODUCTS



The structural diversity of natural products and their easy binding with biomacromolecules determine their incomparable advantages in the process of life regulation and endue natural products with an irreplaceable important position in the research and development of new drugs. Natural products and their molecular frameworks are the primary sources of new drugs.



Library Recommendation


HY-L021P Natural Product Library Plus

This library includes 4,500+ natural compounds containing Saccharides and Glycosides, Phenylpropanoids, Quinones, Flavonoids, Terpenoids and Glycosides, Steroids, Alkaloids, Phenols, Acids, and Aldehydes. Compounds in this library have high structural and 3-dimensionality (3D) diversity, with 2, 000+ Bemis-Murcko scaffolds and an average Fsp3 value of 0.51. All natural products have clear sources and structure classifications. This library is a comprehensive collection of natural products, a valuable tool for drug discovery based on natural products.

HY-L021L Natural Product-like Compound Library

This library includes nearly a thousand natural product-like compounds that are structurally like Steroids, Tannins, Flavonoids, Quinones, Isoquinolines, etc. This library is an important source of lead compounds for drug discovery.

Other Natural Products Series



DRUG DISCOVERY BASED ON STRUCTURE



Different product structures determine different functions. For example, compounds with covalent reactive groups can bind irreversibly to target through covalent bonds, which can lead to the development of highly selective inhibitors and overcoming drug resistance



Library Recommendation

HY-L036P Covalent Screening Library Plus

This library contains 3, 000+ small molecules, including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc. This library is a valuable tool for covalent drug discovery.



Other Recommended Compound Libraries

HY-L036	HY-L138	HY-L041	HY-L033 Peptidomimetic Library
Covalent Screening	Heterocyclic Compound	Macrocyclic Compound	
Library	Library	Library	
HY-L105 Peptide Library	HY-L110 Cyclic Peptide Library	HY-L042 Glycoside Compound Library	HY-L043 Lipid Compound Library

HY-L044

Nucleotide Compound Library



Publications Citing Use of MedChemExpress Compound Libraries

Food Chem. 2023 Jul 1;413:135598.

Signal Transduct Target Ther. 2022 Aug 15;7(1):288.

Circulation. 2022 Apr 12;145(15):1154-1168.

Protein Cell. 2022 Sep 28;14(1):17-27. Nat Commun. 2023 Mar 28;14(1):1726.

Nat Microbiol. 2023 Jan;8(1):121-134.

Free Radic Biol Med. 2023 Apr 10;203:86-101.

Circulation. 2022 Apr 12;145(15):1154-1168.

J Med Chem. 2022 Aug 25;65(16):11058-11065.

J Med Virol. 2021 Oct;93(10):5825-5832.

Cell Stem Cell. 2022 Apr 7;29(4):545-558.e13.

Cell Mol Immunol. 2023 Mar 2;1-14.

Compound Screening Libraries -

SCREENING BASE ON TARGETS AND SIGNALING PATHWAYS

Cell signaling pathways are involved in the pathophysiology of many diseases. The mutations, molecular damage, or functional change of the proteins in the signaling pathway will cause diseases. Therefore, knowledge of basic cell signaling mechanisms are essential to understand pathophysiologic and pharmacologic mechanisms.

MedChemExpress can supply more than 60, 000 bioactive compounds, covering 1, 000+ targets and 20+ hot signaling pathways, including GPCRs, Epigenetics, Immunology/Inflammations and cell proliferation, etc. These compounds are important tools for drug discovery based on targets and signaling pathways.



Cell Death Series

HY-I 003 HY-I 029 HY-I 051

Apoptosis Compound Autophagy Compound Ferroptosis Compound Library Library Library

HY-I 059 HY-I 133

Pyroptosis Compound Cuproptosis Compound Library Library

Metabolism Series

HY-L012	HY-L058	HY-L064
Metabolism/Protease	Glycolysis Compound	Glutamine Metabolism
Compound Library	Library	Compound Library
HY-L030	HY-L078	HY-L084
Human Endogenous	Gut Microbial Metabolite	Microbial Metabolite
Metabolite Compound Library	Library	Library
HY-L123	HY-L091	HY-L092
Human Metabolite	Lipid Metabolism	Glucose Metabolism
Library	Compound Library	Compound Library




According to Signaling Pathway or **Protein Family**

HY-L004 HY-L005 HY-L006 Cell Cycle/DNA Damage **Epigenetics Compound** GPCR/G protein Compound Library Compound Library Library

HY-L007	HY-L008	HY-L009
Immunology/Inflammation Compound Library	JAK/STAT Compound Library	Kinase Inhibitor Library
HY-L010	HY-L011	HY-L013
MAPK Compound Library	Membrane Transporter/ Ion Channel Compound Library	Neuronal Signaling Compound Library
HY-L014	HY-L015	HY-L016
NF-κB Signaling Compound Library	PI3K/Akt/mTOR Compound Library	Protein Tyrosine Kinase Compound Library
HY-L017	HY-L018	HY-L020
Stem Cell Signaling Compound Library	TGF-beta/Smad Compound Library	Wnt/Hedgehog/Notch Compound Library
HY-L024	HY-L037	HY-L038
Histone Modification Research Compound Library	Antioxidant Compound Library	Differentiation Inducing Compound Library
HY-L039	HY-L045	HY-L050
Reprogramming Compound Library	Oxygen Sensing Compound Library	Ubiquitination Compound Library
HY-L054	HY-L060	HY-L062
Endoplasmic Reticulum Stress Compound Library	Cytoskeleton Compound Library	Neurotransmitter Receptor Compound Library
HY-L072	HY-L081	HY-L088
Exosomes Compound Library	Phosphatase Inhibitor Library	Angiogenesis-Related Compound Library
HY-L089	HY-L090	HY-L095
Mitochondria-Targeted Compound Library	Transcription Factor-Targeted Library	Mechanoreceptors Compound Library
HY-L117	HY-L118	HY-L119
Calcium Channel Blocker Library	Sodium Channel Blocker Library	Potassium channel compound library
HY-L120	HY-L121	HY-L126
GABA Receptor Compound Library	5-HT Receptor Compound Library	Nuclear Receptor Compound Library
HY-L128	HY-L129	HY-L109
E3 Ligase Ligand Library	Target Protein Ligand Library	Protein-protein Interaction Inhibitor Library
HY-L131	HY-L132	HY-L136
Osteogenesis Compound Library	Chemokine Compound Library	Coagulation and Anticoagulation Compound Library

Compound Screening Libraries -

DRUG DISCOVERY BASED ON DISEASE





Anti-Cancer Series

HY-L025	HY-L031	HY-L083
Anti-Cancer Compound	Small Molecule Immuno-Oncology	Anti-Cancer Metabolism
Library	Compound Library	Compound Library
HY-L080	HY-L112	HY-L122
Targeted Therapy Drug	Chemotherapy Drug	FDA-Approved Anticancer
Library	Library	Drug Library
HY-L074	HY-L075	HY-L077
Anti-Breast Cancer	Anti-Lung Cancer	Anti-Pancreatic Cancer
Compound Library	Compound Library	Compound Library
HY-L079	HY-L101	HY-L103
Anti-Blood Cancer	Anti-Liver Cancer	Anti-Colorectal Cancer
Compound Library	Compound Library	Compound Library
HY-L124	HY-L135	HY-L107
Anti-Prostate Cancer	Cancer Stem Cells	Anti-Cancer Natural
Compound Library	Compound Library	Product Library



Neurodegenerative Disease Series

HY-L085 HY-L086 HY-L070

Anti-Parkinson's Disease Neurodegenerative Disease-Related Neuroprotective **Compound Library** Compound Library Compound Library

HY-L069

Anti-Alzheimer's disease **Compound Library**



Anti-Infection Series

HY-L002	HY-L048	HY-L049
Anti-Infection Compound	Antifungal Compound	Antibacterial Compound
Library	Library	Library
HY-L067 Antibiotics Library	HY-L082 Antiparasitic Compound library	HY-L027 Antiviral Compound Library
HY-L052	HY-L073	HY-L113
Anti-COVID-19	Anti-Hepatitis C Virus	Antiviral Traditional Chinese
Compound Library	Compound Library	Medicine Active Compound Library
HY-L127 Anti-Orthopoxvirus Compound Library		



∴ Other Disease Related Compound Libraries

HY-L125	HY-L130	HY-L034
Anti-Pulmonary Fibrosis Compound Library	Non-Steroidal Anti-Inflammatory Compound Library	Anti-Aging Compound Library
HY-L040	HY-L046	HY-L047
Diabetes Related Compound Library	Anti-Cardiovascular Disease Compound Library	Endocrinology Compound Library
HY-L087	HY-L102	HY-L108
Anti-Diabetic Compound Library	Rare Diseases Drug Library	Antidepressant Compound Library
HY-L134 Anti-Aging Natural	HY-L139 Pain-Related Compound	
Product Library	Library	



Publications Citing Use of MedChemExpress Compound Libraries

J Exp Clin Cancer Res. 2023 Feb 9;42(1):45. Food Chem. 2023 Jul 1;413:135598.

Nat Commun. 2023 Mar 28;14(1):1726.


Small. 2023 Apr;19(16):e2207194.

Plant Biotechnol J. 2023 Jan;21(1):63-77. Cancer Immunol Res. 2023 May 3;11(5):583-599.

Sci Adv. 2023 Mar;9(9):eade3760. J Transl Med. 2023 Mar 9;21(1):184. Nat Cancer. 2022 May;3(5):614-628.

Compound Screening Libraries —

DRUG SCREENING BASED ON PRODUCT FEATURES





Library Recommendation

HY-L028 CNS-Penetrant Compound Library

This library contains nearly 1,000 compounds with confirmed CNS-Penetrant properties. It's a valuable tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L061 Orally Active Compound Library

Most drugs available in the marketplace are administered via the oral route, which is a convenient and cost-effective route of administration. Thus, oral bioavailability is one of the critical considerations in drug design and development. MedChemExpress offers a unique collection of 3,000+ compounds with confirmed high oral bioavailability. MedChemExpress Orally Active Compound Library is a valuable tool for discovering new drugs with oral bioavailability.



Other recommended Compound Libraries

HY-L023	HY-L100	HY-L094
Toxins for Antibody-Drug Conjugate Research Library	Tumorigenesis-Related Compound Library	Food-Sourced Compound Library
HY-L063	HY-L076	HY-L093
Chemical Probe Library	Drug-Induced Liver Injury(DILI) Compound Library	Food Additive Library
HY-L096	HY-L097	HY-L098
Inactive Ingredient Library	Animal Disease Model Inducer Library	Drug Metabolite Library
HY-L137	HY-L151	
Molecular Glue Compound Library	PROTAC Library	

08.

It is proved that a diverse compound library is the most successful and straightforward starting point to discover new leads because it contains highly dissimilar new chemical scaffolds. **MedChemExpress** can provide a series of diverse compound libraries.

DIVERSITY COMPOUND LIBRARIES



HY-L901 50K Diversity Library

A representative diversity set, average Tanimoto coefficient of 0.508. Highly recommended for random screening against new as well as popular targets based on its novel, diverse scaffolds, abundant chemical spaces and the convenience for subsequent modification.

HY-L902 5K Scaffold Library

An exceptionally diverse library, each compound represents one unique scaffold. The sufficient diversity of compound structure makes this library a powerful tool for preliminary hits screening.

HY-L903 3D Diverse Fragment Library

This library comprises 5,196 non-flat fragment-like compounds and is designed based on 3D structure for structural diversity and reactivity. This brings higher fragment hit optimization and increases the likelihood of finding innovative hits in FBDD.

HY-L910V **50K Virtual Diversity Library**

A novel collection of 50,000 synthetically accessible, lead-like compounds with exceptional structural diversity. Compounds in this library are easy to synthesize via standard 1-2 step procedures.

HY-L912V 10M Virtual Diversity Library

A unique collection contains 10,000,000 synthetically accessible screening compounds. This library is highly recommended for Al-based lead discovery, ultra-large virtual screening, and novel lead discovery.

High throughout libraries with more than 26 million compounds

These libraries come from different internationally renowned brands. They are not only suitable for virtual screening, but also for various in vitro drug screening experiments for new drug discovery.

Compound Screening Libraries —



DEL I IBRARY



DNA Encoded Compound Library (DEL) technology has emerged as an enabling tool in the drug discovery field; featured an incredibly convenient and rapid way to assess the binding affinity of billions of chemical compounds and discover potential ligands for biological and pharmaceutical interested protein targets. Based on more than 50,000 high-quality building blocks, combined with hundreds of DNA-compatible reactions, MedChemExpress synthesized a series of DNA-encoded libraries consisting of billions of compounds with abundant chemical spaces and novel structures.



7 3 Kits

DFL A Kit

20 DEL libraries, covering over 300 million DEL molecules, 1 tube set

DEL T Kit

68 DEL libraries, covering over 2 billion DEL molecules. 1 tube set

DFL B Kit

50 DEL libraries, covering over 1 billion DEL molecules. 1 tube set

5~ 1

🕇 Mini DEL library

DEL C Kit Covalent library

5 DEL libraries, covering over 3 million DEL molecules. 1 tube set

DEL D Kit Cyclic peptide library

5 DEL libraries, covering over 8 million DEL molecules, 1 tube set

DEL E Kit Regular library

5 DEL libraries, covering over 190 million DEL molecules, 1 tube set

DEL F Kit Regular library

5 DEL libraries, covering over 109 million DEL molecules, 1 tube set

DEL G Kit Regular library

5 DEL libraries, covering over 113 million DEL molecules. 1 tube set

DEL H Kit Regular library

10 DEL libraries, covering over 550 million DEL molecules, 1 tube set



DEL Library Customized Service

Depending on the specific building block structure of your request, **MedChemExpress** can provide customized DEL synthesis service. Through the use of cutting-edge technologies, **MedChemExpress**'s robust and professional DEL synthesis team have been developed more than 100 different types of chemical reactions in the presence of a DNA tag.

10.

CUSTOMIZE YOUR LIBRARIES

Any customization can be made according to your needs



MedChemExpress

Master of Bioactive Molecules

Compound Screening Libraries —

11

CASE STUDIES



MedChemExpress Anti-cancer Compound Library Assisted the Mechanism Study and Drug Discovery of Sox10-deficient Melanomas


Background

SOX10 is heterogeneously expressed in melanomas. Loss of SOX10 reduces proliferation, leads to invasive properties, and promotes tolerance to BRAF and/or MEK inhibitors. After taking high throughput screening using **MedChemExpress** anti-cancer library (Cat. No: HY-L025), all five cIAP1/2-XIAP inhibitors included in the screen effectively induced cell death in SOX10 knockout cells with little-to-no effect on parental cells. Thus, cIAP1 and/or cIAP2 may be relevant targets for causing cell death in SOX10 knockout cells.

Further studies showed that cIAP2 is a crucial target for inducing cell death in SOX10 knockout cells.

Conclusion

cIAP1/2 inhibitors can delay the onset of acquired resistance to BRAF/MEK inhibitors in melanomas in vivo.



Nat Commun. 2022 Mar 16;13(1):1381.



MedChemExpress Compound Library Assists in Building of NIH Screening Platform

The NIH Chemical Genomics Center (NCGC) is an ultrahigh-throughput screening center of the Molecular Libraries Probe Production Centers Network (MLPCN) that owns advanced HTS equipment and testing instruments. MedChemExpress continuously supplies tens of thousands of compounds to the platform, some of which are hundreds of milligrams in size, providing strong support for its platform building and maintenance.





MedChemExpress Compound Library Powers the Disease Study of St. Jude Children's Research Hospital

St. Jude Children's Research Hospital (St. Jude) is a comprehensive research center designated by the National Cancer Institute for the treatment of childhood cancer, with rich experience in basic research and clinical transformation in pediatric disease research.

In recent years. MedChemExpress has established a stable cooperation relationship with St. Jude as a quality supplier to the Screening Center of St. Jude; continuously supplies dozens of compound libraries, with tens of thousands of compounds, it supports drug discovery and disease research at St. Jude.





MedChemExpress Compound Libraries Promote Drug Discovery in the Early Stage

MedChemExpress compound Libraries have been widely recognized by large pharmaceutical companies worldwide. MedChemExpress has become a stable supplier of pharmaceutical enterprises and continuously supplies a large number of high-quality compound libraries for accelerating drug early development.

























12.

PARAMETERS OF MCE BIOACTIVE COMPOUND LIBRARY

96-well Format Sample Storage Tube



96-/384- well Plate



Specifications	30 μL, 50 μL, 100 μL or other size lower than 500 μL	30 μL, 50 μL, 100 μL or other size lower than 100 μL
Sealing Way	Screw Cap	Peelable Foil Seal
Concentration		ution state and solubility no less than 10 mM; olubility between 2 mM and 10 mM; nolecular weight and solubility no less than 3 mg/ml
Solvent	DMSO, Wa	ter, Ethanol
Recommended Storage Time	Powder: -20°C (3 yo In solvent: -80°C (2 y	ears); 4°C (2 years) /ears); -20°C (1 year)
Information Shipped with Library		ty information, research areas, clinical data, etc.; t for each plate; es some specialized software to open (ChemOffice).
Plate Layout Plate Layout Compounds with different concentrations or dissolved in different solutions are put of you have any other requirements for the layout of compounds, please let us know before the concentration of the layout of compounds, please let us know before the layout of compounds, please let us know before the layout of compounds, please let us know before the layout of compounds, please let us know before the layout of compounds, please let us know before the layout of compounds, please let us know before the layout of compounds, please let us know before the layout of compounds.		Empty ved in different solutions are put on separate plates.



Virtual Screening is an effective tool for rapidly screening of millions of compounds with reasonable binding patterns and potential druggability. It is based on the molecular docking of compounds in the druggable pocket on a target protein. It can bypass primary wet-lab screening hence, reducing the time and cost of novel drug discovery.




Advantages

- High-performance computer servers
- All kinds of different libraries (>16 million compounds)
- High standard intellectual property management (confidentiality)
- Experienced professionals for molecular docking and drug design
- SCI publishable 2D/3D molecular docking figures can be provided



Example

Virtual screening for the discovery of GPD1 allosteric activator and analysis of the GPD1-compound binding model.



A. Crystal structure of GPD1 protein (PDB ID:6E8Y). Red represents the predicted allosteric sites.

B. Representation of GPD1 protein with compounds discovered by virtual screening.

J Hematol Oncol. 2022 Jul 14;15(1):93.



DRUG SCREENING SERVICES

AS-MS **SCRFFNING**

MedChemExpress offers AS-MS (Affinity Selection-Mass Spectrometry) screening to support the identification of compounds with strong affinity and specificity for a target protein, which could be a perfect starting point for your novel drug discovery projects.



AS-MS Screening Process



Advantages

- Several successful projects with repeatability and high consistency
- Customized and cost-effective service
- High standard intellectual property management (confidentiality)
- Experienced professionals and cutting-edge facility

02.

TARGET BASED SCREENING (GPCR/ KINASE/ **ION CHANNEL)**



Around half of the approved drug targets are GPCRs, kinases, ion channels, and nuclear receptors, and 70% of the approved small molecule drugs are targeted against these four types.

MedChemExpress can do compound screening with hundreds of stable cell lines specifically for GPCRs and ion channels. For kinase screening & profiling, we can provide both in vitro and in vivo screening services. A bunch of different screening methods would be customized based on your requests.

30+ Ion Channel Assay Models



- Platforms of different throughputs: Qpatch16X, QpatchHTX, lonWorks Barracuda
- Gold standard: manual patch clamp
- Fluorescent platform: FLIPR, FDSS/µCell

100+ GPCR Stable Cell Lines



- Multiple assays formats, including calcium flux, cAMP determination
- FLIPRPENTA (EMC-CD), BMGPHERAstar FSX, BIOTEK multifunctional plate reader
- Customized GPCR stable cell line construction

400+ Kinase



- A long list of kinas: AGC, CAMK, CMGC, CK1, STE, and common mutants
- Flexible and customizable kinase panel: 60/207/302 kinase panels and customized kinase panels
- Various detection: TR-FRET, fluorescence, Z`-LYTE, binding assay

03.

ANTI-CANCER COMPOUND SCREENING IN VITRO



MedChemExpress compound activity screening (anti-cancer compound screening in vitro) platform takes the whole cell as the research object, and can provide a variety of cell proliferation and cytotoxicity detection services. We can also detect the effect of compounds on cell apoptosis, cell cycle to obtain a large amount of relevant information from a single experiment, determine the biological activity and potential toxicity of the compound.











Prepare Cells

Prepare Compounds

Add Compounds

Data Acquisiton

Data Anylasis

🟠 Advantages

- 120+ tumor cell lines
- A variety of cell viability assays
- The professional compound screening team
- Advanced equipments
- Experienced professionals and high resolution imaging system


04

DEL SCREENING



MedChemExpress's one-stop DEL screening platform consists of not only a series of in-stock DEL libraries such as photo-cross-linking DELs, covalent DELs, cyclic peptide DELs, but also DEL customized service, and DEL screening service.

Customized DEL synthesis service can be provided depending on any specific building block structure request. Through the use of cutting-edge technologies, **MedChemExpress**'s strong and professional DEL synthesis team has developed more than 100 different types of chemical reactions in the presence of DNA tag.



Overview of DNA-Encoded Library (DEL) Technology.

(A) DEL Synthesis. (B) DEL Screening.

Advantages

- 68 DEL libraries, covering billions of DEL molecules.
- Novel chemical structure, comprehensive chemical space coverage, and drug-like molecular characteristics
- Strict quality control and verification system
- Tailor-made DEL library

- Keep up with research trends and keep updating
- A small amount of protein sample: about 100 μg protein (depending on the protein's molecular weight)
- Short lead time and high cost performance



LEAD COMPOUND OPTIMIZATION

Lead compounds obtained by high-throughput screening may have problems, such as high toxicity, poor metabolic stability in vivo, and low bioavailability. So the structures need to be further optimized. **MedChemExpress** can provide lead compound analogs search and supply, custom synthesis, chemical analysis, and detection services.

SEARCH AND SUPPLY OF STRUCTURE ANALOGS

- Deep analysis of screening hits and hit classification into chemical families
- · Search for structural analogs in the available chemical space
- Supply and custom synthesis of structural analogs

02. CUSTOM SYNTHESIS

MedChemExpress is committed to the custom synthesis of complex compounds with high challenges. **MedChemExpress** has built an experienced chemical synthesis team with hundreds of advanced equipment, and established a set of perfect custom synthesis service systems, which can scale up from milligrams to kg scale to meet different customer needs.

O3. ANALYTICAL DEVELOPMENT & QUALITY CONTROL

- R&D testing
- Analytical method development and validation
- Impurity preparation, separation, and purification
- · Genotoxic impurity research

- Structure characterization and impurity analysis
- Stability study
- Registration application services